JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

Journal of Alzheimer's Disease, published by IOS Press, stands as a pivotal resource in the fight against Alzheimer's and related neurodegenerative disorders. With an ISSN of 1387-2877 and an E-ISSN of 1875-8908, this esteemed journal has evolved since its inception in 1998, providing a vital platform for academic research and clinical practice in the realms of Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Ranked in the Q1 category across several disciplines, including Clinical Psychology and Geriatrics, this journal not only highlights significant advancements in understanding Alzheimer's disease but also fosters interdisciplinary dialogue among researchers, healthcare professionals, and policymakers. Boasting robust Scopus rankings—such as 49th in Clinical Psychology and 29th in Geriatrics—this journal is committed to disseminating high-quality research that informs both therapeutic strategies and public health initiatives. The Journal of Alzheimer's Disease is an essential resource for anyone dedicated to exploring the complexities of cognitive decline and enhancing care for affected individuals.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

AGEING RESEARCH REVIEWS, published by Elsevier Ireland Ltd, is a prestigious academic journal dedicated to advancing our understanding of the biological, psychological, and societal aspects of aging. With an ISSN of 1568-1637 and E-ISSN of 1872-9649, this journal has established itself as a leading resource in the fields of Aging, Biochemistry, Biotechnology, Molecular Biology, and Neurology, consistently ranked in the Q1 category across these disciplines as of 2023. For researchers, students, and professionals eager to explore cutting-edge findings and innovative methodologies, AGEING RESEARCH REVIEWS gathers comprehensive reviews that facilitate a deeper understanding of age-related processes. Its high impact factor and exceptional Scopus rankings—ranking #1 in Aging and #3 in Neurology—underscore its critical role in shaping contemporary aging research. This journal not only serves as a vital reference point but also fosters a collaborative space for the scientific community focused on improving health outcomes across the life span. Published continuously since 2002 and with a converging focus through 2024, AGEING RESEARCH REVIEWS remains committed to disseminating impactful knowledge that drives progress in our understanding of the aging process.

CURRENT OPINION IN NEUROLOGY is a premier academic journal dedicated to providing insightful overviews and critical analyses across all areas of neurology and clinical neurology. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an impressive impact factor, highlighting its influence and relevance in the field—positioning it in the Q1 category for both neurology and clinical neurology as of 2023. With its comprehensive coverage, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to stay abreast of the latest developments, trends, and breakthroughs in neurological science and practice. Though not open access, articles are available via institutional subscriptions or individual purchase, ensuring that vital research remains accessible to a wide audience. Covering research from its inception in 1993 to ongoing studies in 2024, CURRENT OPINION IN NEUROLOGY stands out as an essential platform for disseminating knowledge and fostering dialogue within the dynamic and evolving landscape of neurology.

Turkish Journal of Neurology, published by GALENOS PUBL HOUSE, is a pivotal open-access journal established in 2004, dedicated to advancing the field of neurology. Renowned for its inclusive approach, this journal serves as a vital platform for researchers and clinicians to share their findings and insights related to neurological disorders and clinical practices, with an emphasis on enhancing the understanding of various neurological conditions affecting populations in Turkey and beyond. Although it holds a Q4 rank in Neurology (Clinical) as per the 2023 category quartiles, the journal's commitment to fostering knowledge exchange remains steadfast, aiming to bridge gaps in clinical research and practice. With an ISSN of 1301-062X and an E-ISSN of 1309-2545, it is indexed in Scopus, ranking 349 out of 400, reflecting its growing presence in the academic sphere. Located in Istanbul, Turkey, the journal invites submissions from both emerging and established researchers to contribute to its diverse content, thereby enhancing its impact on the local and international neurology community.

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, published by Lippincott Williams & Wilkins, is a pivotal journal for advancing knowledge in the fields of clinical psychology, geriatric medicine, and psychiatry. With a history spanning from 1987 to 2024, this journal provides a comprehensive platform for researchers and clinicians to disseminate significant findings related to Alzheimer's disease and associated cognitive disorders. Ranked within the second and third quartiles in various categories, including clinical psychology and geriatrics, it retains a solid academic reputation, indicated by its diverse Scopus rankings, such as #137 in Clinical Psychology and #20 in Nursing & Gerontology. Although it does not offer open access, the journal is recognized for its commitment to peer-reviewed research, making it a valuable resource for professionals and students alike, aiming to stay abreast of the latest developments and evidence-based practices in Alzheimer’s and associated conditions.

Alzheimer's & Dementia: Translational Research & Clinical Interventions, published by WILEY, is a premier open-access journal that has been at the forefront of innovations in the field of neurology and psychiatry since its inception in 2015. With an impressive impact factor reflecting its high-quality research contributions, this journal has been designated as Q1 in both Neurology (Clinical) and Psychiatry and Mental Health categories for 2023, ranking in the top percentiles of their respective Scopus fields. The journal aims to bridge the gap between research and clinical practice, promoting the translation of scientific discoveries into real-world applications for Alzheimer's disease and other dementias. Positioned in the United States, it is a valuable resource for researchers, clinicians, and students dedicated to advancing knowledge and treatment approaches in these critical areas. With its commitment to open access, the journal ensures that vital research is accessible to a broad audience, fostering collaboration and knowledge sharing across the global scientific community.

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS is a distinguished peer-reviewed journal published by KARGER, based in Switzerland. With a focus on the critical fields of cognitive neuroscience, geriatrics, and psychiatry, this journal is integral to advancing our understanding of cognitive decline and geriatric health. Despite being established from 1990 through 1992 and relaunching its scope in 1994, it has consistently provided a platform for innovative research, as reflected in its strong impact factor and notable Scopus rankings, placing it in the Q2 quartile for disciplines including cognitive neuroscience and geriatric medicine. The journal aims to foster interdisciplinary dialogue and collaboration among researchers, healthcare professionals, and educators, contributing to the growing field of dementia research and elderly care. Open access options further ensure that this vital knowledge is widely accessible, making a significant impact in both academic and clinical settings. With a commitment to quality and relevance, DEMENTIA AND GERIATRIC COGNITIVE DISORDERS remains a key resource for those dedicated to understanding and addressing the challenges posed by cognitive disorders in aging populations.